Foundation Medicine Inc (NASDAQ:FMI) CFO Jason Ryan sold 15,000 shares of the company’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $78.26, for a total value of $1,173,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Jason Ryan also recently made the following trade(s):
- On Thursday, February 15th, Jason Ryan sold 15,000 shares of Foundation Medicine stock. The stock was sold at an average price of $67.53, for a total value of $1,012,950.00.
- On Tuesday, January 16th, Jason Ryan sold 21,035 shares of Foundation Medicine stock. The shares were sold at an average price of $64.38, for a total value of $1,354,233.30.
- On Tuesday, January 2nd, Jason Ryan sold 2,336 shares of Foundation Medicine stock. The shares were sold at an average price of $64.00, for a total value of $149,504.00.
Shares of Foundation Medicine stock traded up $0.95 during mid-day trading on Monday, reaching $80.80. The company had a trading volume of 563,765 shares, compared to its average volume of 319,516. The stock has a market cap of $2,945.01, a PE ratio of -17.96 and a beta of -0.21. Foundation Medicine Inc has a 52 week low of $29.90 and a 52 week high of $87.10. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.86 and a quick ratio of 1.67.
Foundation Medicine (NASDAQ:FMI) last issued its earnings results on Wednesday, March 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). The company had revenue of $48.90 million for the quarter, compared to analysts’ expectations of $48.69 million. Foundation Medicine had a negative net margin of 105.60% and a negative return on equity of 207.73%. The company’s revenue was up 69.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.02) earnings per share. research analysts anticipate that Foundation Medicine Inc will post -4.22 EPS for the current fiscal year.
Several brokerages recently weighed in on FMI. BidaskClub cut Foundation Medicine from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Zacks Investment Research upgraded Foundation Medicine from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a report on Wednesday, December 6th. Cowen began coverage on Foundation Medicine in a report on Thursday, February 15th. They set an “outperform” rating and a $90.00 target price for the company. Finally, Wells Fargo restated a “market perform” rating and set a $80.00 target price (up from $67.00) on shares of Foundation Medicine in a report on Thursday, March 8th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $69.60.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its position in Foundation Medicine by 215.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,786 shares of the company’s stock valued at $393,000 after purchasing an additional 6,686 shares during the last quarter. Macquarie Group Ltd. raised its position in Foundation Medicine by 33.3% during the 3rd quarter. Macquarie Group Ltd. now owns 106,603 shares of the company’s stock valued at $4,285,000 after purchasing an additional 26,603 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Foundation Medicine by 4.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 63,030 shares of the company’s stock valued at $2,534,000 after purchasing an additional 2,803 shares during the last quarter. SG Americas Securities LLC raised its position in Foundation Medicine by 36.6% during the 3rd quarter. SG Americas Securities LLC now owns 6,481 shares of the company’s stock valued at $261,000 after purchasing an additional 1,736 shares during the last quarter. Finally, Boston Advisors LLC bought a new position in Foundation Medicine during the 4th quarter valued at approximately $13,000,000. 29.23% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Foundation Medicine Inc (FMI) CFO Jason Ryan Sells 15,000 Shares” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/19/foundation-medicine-inc-fmi-cfo-jason-ryan-sells-15000-shares.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.